Tenderwize
Back to tender search

Pharmaceutical products for Amgros 2027

Amgros I/S·København Ø, Denmark·DKK 5.1M | EUR 685k·Deadline Aug 20, 2026 · 5 days left·Open·Supplies·Framework
Original notice title

Denmark – Pharmaceutical products – Amgros 2027 1.182.a

63/100

Opportunity Score

Needs reviewMedium complexity
SuppliesFrameworkOpen
Why this score?

Opportunity

63 / 100

Complexity

45 / 100

Risk factors

The structured overall estimated value is DKK 5,120,000, while the XML notice also shows a higher framework maximum amo...

The portal link is present, but no procurement document text was extracted, so detailed contract terms, submission inst...

Submission deadline in 5 days

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • DKK 5.1M estimated value
  • Framework procurement
  • Supplies contract
  • 2 lots
  • Duration until Dec 2028
  • Supply of pharmaceutical products under framework agreements for hospital pharmacies in the five Danish regions.
  • Two independent lots for Polatuzumab vedotin (ATC L01FX14) in different strengths.
Show full summary

Open framework-agreement tender by Amgros I/S for pharmaceutical products (CPV 33600000) in Denmark, split into 2 independent lots for Polatuzumab vedotin. Electronic submission is required via the Amgros portal. The notice indicates no minimum suitability requirements and a price-only award criterion. Estimated overall contract value is DKK 5,120,000; the XML also shows a framework maximum amount of DKK 5,738,985, which is higher than the structured overall estimate.

Risks

The structured overall estimated value is DKK 5,120,000, while the XML notice also shows a higher framework maximum amo...

The portal link is present, but no procurement document text was extracted, so detailed contract terms, submission inst...

Submission deadline in 5 days

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Open procedure.
  • Framework agreements are non-exclusive and without purchase obligation.

Administrative

  • Electronic submission required.

Award Criteria

Lot 1

Price (100%, per-exa)100%

Lot 2

Price (100%, per-exa)100%

Buyer

Location

København Ø, DNK

Buyer profile

Open profile

Identifier

14479880

Activity

Health

Lots (2)

LOT-0001

Polatuzumab vedotin 30 mg infusion solution

Independent framework lot for Polatuzumab vedotin, infusion solution, strength 30 mg, with an estimated quantity of 99 units. The lot is non-exclusive, without purchase obligation, and may be awarded separately from the other lot. Place of performance is Denmark (DK011).

SuppliesFrameworkEU fundedElectronic submission

EUR 685k

Estimated value

Location

DK011, Denmark

Duration

Dec 2026 - Dec 2028

Category

Pharmaceutical products

Award Criteria

Price

Deadline

Deadline Aug 20, 2026

LOT-0002

Polatuzumab vedotin 140 mg infusion solution

Independent framework lot for Polatuzumab vedotin, infusion solution, strength 140 mg, with an estimated quantity of 117 units. The lot is non-exclusive, without purchase obligation, and may be awarded separately from the other lot. Place of performance is Denmark (DK011).

SuppliesFrameworkEU fundedElectronic submission

EUR 685k

Estimated value

Location

DK011, Denmark

Duration

Dec 2026 - Dec 2028

Category

Pharmaceutical products

Award Criteria

Price

Deadline

Deadline Aug 20, 2026

Procurement Details

Publication date
29 Jun 2026
Languages
Danish, Swedish

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
446664-2026

Documents (1)

Similar tenders